Anti-TGFb1 antibody
Specifications
| Product Cat#: | AB-06-4322 |
| Product type: | Primary antibody |
| Antigen: | TGFb1 |
| Immunogen: | Recombinant protein |
| Species immunized: | Mouse |
| Isotype: | IgG1 |
| Applications: | Western Blot (1:400-1:1000); Immunohistochemistry (1:50-1:500); Flow Cytometry (1:50-1:200) |
| Reactivity: | Human |
| Clonality (clone number): | Monoclonal (B2-F6) |
| Form: | Liquid |
| Buffer: | Tris-HCl buffer (pH7.4), 1% BSA, 40% glycerol, 0.05% NaN3. |
| Concentration: | 1 mg/ml |
| Purity: | Protein A affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: |
Target information
Transforming growth factor beta-1 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains, which constitute the regulatory and active subunit of TGF-beta-1, respectively.
Latency-associated peptide: Required to maintain the Transforming growth factor beta-1 (TGF-beta-1) chain in a latent state during storage in extracellular matrix (PubMed:28117447). Associates non-covalently with TGF-beta-1 and regulates its activation via interaction with ‘milieu molecules’, such as LTBP1, LRRC32/GARP and LRRC33/NRROS, that control activation of TGF-beta-1. Interaction with LRRC33/NRROS regulates activation of TGF-beta-1 in macrophages and microglia (Probable). Interaction with LRRC32/GARP controls activation of TGF-beta-1 on the surface of activated regulatory T-cells (Tregs). Interaction with integrins (ITGAV:ITGB6 or ITGAV:ITGB8) results in distortion of the Latency-associated peptide chain and subsequent release of the active TGF-beta-1.
Provider
Erpantech Laboratory